Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$134.50
-$1.43(-1.02%)
At close: 4:00 PM EST
$134.50
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$88.00 - $196.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.09M
Market Cap
$28.42B
Enterprise Value$25.53B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)35.0
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,300,000
10 Day Avg. Volume2,080,440
30 Day Avg. Volume2,092,370
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue5.81
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda18.13
Forecast
1Y Price Target
$158.57Price Target Upside17.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.23
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
Consumables Recurring Revenue (razor-and-blades)Illumina's platform economics create a durable recurring revenue stream: once instruments are installed customers purchase proprietary reagents and flow cells repeatedly. This installed-base pull-through provides predictable replacement demand and supports long-term cash flow and margin sustainability.
Strong Cash Generation And Improved MarginsRobust operating and free cash flow, with FCF near 88% of net income, signals durable cash conversion. That supports ongoing R&D, capacity expansion, buybacks and resilience during cyclical revenue periods, improving Illumina's ability to fund growth and return capital over the medium term.
NovaSeq X Installed-base Adoption And Throughput GainsRapid transition to NovaSeq X is a structural competitive advantage: higher throughput and share of volume drive greater consumables pull-through and stickiness. Widespread X adoption improves unit economics, increases sequencing output capacity, and supports durable margin and consumable revenue growth.
Bears Say
Research & Applied Consumables WeaknessSustained weakness in research consumables reflects funding and demand headwinds that can cap top-line growth. Because research was historically a key growth engine, prolonged cutbacks reduce visibility into incremental consumables volume and slow the installed-base monetization trajectory over the medium term.
Microarrays Revenue DeclineA sharp decline in microarrays points to structural erosion of legacy product revenues and limited diversification. If the core business shifts away from older offerings, Illumina must replace that revenue with sequencing growth, increasing reliance on a smaller set of products and customer segments over time.
Weakened Balance-sheet CushionAlthough leverage is manageable, materially reduced equity versus prior years means less capital cushion in downturns. A thinner equity base limits flexibility for large M&A, debt tolerance, or aggressive capital deployment if cash generation weakens, increasing financial risk over a multi-quarter stress period.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $88.00 and its highest was $196.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $28.42B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 30, 2026 which is in 20 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.095.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.23.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.15 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 7.133%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$158.57 (17.90% Upside)
$158.57 (17.90% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 789.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.85%
12-Months-Change
Fundamentals
Return on Equity
33.99%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear beat in Q1 with multiple key operational and financial positives: revenue and EPS outperformance, strong clinical consumables growth (~20% ex-China), robust NovaSeq X placements (80+ in the quarter), margin expansion, and an upwardly revised full-year guide. Offsetting items include continued weakness in research & applied consumables (down ~12% ex-China), a 20% decline in microarrays RoW organic, supply constraints on NovaSeq X that require scaling investments, and near-term inflationary pressures impacting Q2 margins. Management framed the negatives as transitory or manageable and emphasized product innovation, strong cash flow, and progress toward 2027 targets.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$158.57
▲(17.90% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
28.21% Mutual Funds
0.19% Other Institutional Investors
45.94% Public Companies and Individual Investors